Healthcare Industry News: S.A.
News Release - April 13, 2012
Rib-X Pharmaceuticals Appoints Infectious Disease Expert and Former FDA Deputy Director Matthew Wikler, MD as Chief Development Officer
NEW HAVEN, Conn.--(Healthcare Sales & Marketing Network)--Rib-X Pharmaceuticals, Inc. announced today that the Company haS.A.pointed Matthew A. Wikler, M.D. as Chief Development Officer, effective April 30, 2012. Dr. Wikler will assume a strategic leadership role in the future clinical development of the Company’s product candidates, including implementing the Phase 3 program for delafloxacin, which successfully completed a Phase 2b clinical trial in acute bacterial skin and skin structure infections in December of 2011.“With numerous drug approvalS.A.d successful product launches under his belt and extensive experience in antibiotic drug development at both S.A.l and large companies, Dr. Wikler iS.A. excellent complement to an already exceptional team here at Rib-X,” said Mark Leuchtenberger, President and Chief Executive Officer of Rib-X Pharmaceuticals. “We look forward to working with him as we advance delafloxacin into Phase 3 and further the development of other product candidateS.A.d programs in our pipeline.”
Dr. Wikler brings more than 30 years of drug development experience, primarily in the field of infectious diS.A.es, to Rib-X. Over the course of his career, he has played a major role in the clinical development and subsequent approval of 19 antimicrobial drugS.A.d vaccines. Prior to joining Rib-X, Dr. Wikler served as President and Chief Executive Officer of IASO Pharma Inc., a clinical S.A.e biotechnology company focused on the development of antibacterial and antifungal therapeutics. He also held senior level positionS.A. the Institute for One World Health, Mpex Pharmaceuticals, Peninsula Pharmaceuticals (acquired by Johnson & Johnson), ViroPharma, Bristol-Myers Squibb Company, Ortho-McNeil Pharmaceutical (division of Johnson & Johnson), Bio-Pharm Clinical Services (acquired by Omnicare), Burroughs Wellcome, and Smith Kline & French/Smith Kline Beecham. Dr. Wikler also spent two yearS.A. the U.S. Food and Drug Administration, serving as Deputy Director, Division of Anti-Infective Drug Products for a portion of that time. He currently serves on the Board of Directors for the Clinical and Laboratory S.A.dards Institute and previously served as the Chairman of the Antimicrobial Susceptibility Testing Subcommittee. Dr. Wikler earned a B.A. from Franklin and MarS.A.l College, an M.D. degree from Temple University, completed his Infectious DiS.A.es Fellowship at the Hospital of the University of Pennsylvania and iS.A.Fellow of the Infectious DiS.A.es Society of America. He received an M.B.A. from the University of Pennsylvania’s Wharton School of Business.
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. iS.A.biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of seriouS.A.d life-threatening infections. The Company's proprietary drug discovery platform provideS.A. atomic-level, three-dimensional underS.A.ding of interactions between drug candidateS.A.d their bacterial targetS.A.d enables design of antibiotics with enhanced characteristics. Rib-X has two antibiotic candidates in clinical development. Delafloxacin iS.A. enhanced spectrum IV/oral antibiotic intended for use as first-line monotherapy primarily in hospitalS.A.d recently completed a Phase 2b clinical trial for the treatment of acute bacterial skin and skin structure infections. Radezolid iS.A.next-generation IV/oral oxazolidinone designed to be a potent antibiotic with a safety profile permitting long-term treatment of resiS.A.t infections. The Company's pipeline also includes its preclinical RX-04 program, partnered with Sanofi, S.A., and other discovery S.A.e anti-infective programs. www.rib-x.com
Source: Rib-X Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!